Screener
PTC Therapeutics PTCT Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Other income (expense), net | 1,609 | (6,305) |
| (Loss) income before income tax expense | (2,462) | 929,828 |
| Income tax expense | (347) | (63,266) |
| Net (loss) income attributable to common stockholders | $(2,809) | $866,562 |
| Weighted-average shares outstanding: | ||
| Basic (in shares) | 82,521,023 | 78,115,836 |
| Diluted (in shares) | 82,521,023 | 86,385,922 |
| Net (loss) income per share—basic (in dollars per share) | $(0.03) | $11.09 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's net income?
- PTC Therapeutics (PTCT) reported net income of -$2.81M in Q1 2026.
- How has PTC Therapeutics's net income changed year-over-year?
- PTC Therapeutics's net income decreased by 100.3% year-over-year, from $866.56M to -$2.81M.
- What is the long-term trend for PTC Therapeutics's net income?
- Over 3 years (2021 to 2024), PTC Therapeutics's net income has grown at a -11.5% compound annual growth rate (CAGR), from -$523.9M to -$363.3M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about PTC Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude